Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Mary Kelada"'
Autor:
Mary Kelada, Parizad Avari, Soma Farag, Rashmi Akishar, Rajni Jain, Ahmad Aziz, Claire Feeney, Vassiliki Bravis, Karim Meeran, Vickie Lee
Publikováno v:
Frontiers in Endocrinology, Vol 12 (2021)
BackgroundThyroid eye disease (TED) is a potentially disfiguring and sight-threatening autoimmune (AI) orbitopathy, affecting up to 400,000 people in the UK. There are no accurate early predictors of TED severity. Although polyautoimmunity has been s
Externí odkaz:
https://doaj.org/article/6a1a653e6d314af09c348cfaeb38b135
Publikováno v:
Medical Education Online, Vol 25, Iss 1 (2020)
Externí odkaz:
https://doaj.org/article/6f8a6d8332d24b7da1300c7d56380c24
Publikováno v:
Cutis. 109
Blisters and subsequent desquamation of the skin in the presence of acute edema is a well-known clinical phenomenon. In this case report, we describe a new variant that we have termed anasarca-induced desquamation in a 50-year-old man with molting of
Publikováno v:
Expert Review of Ophthalmology. 16:33-46
Glaucoma remains the leading cause of irreversible blindness. Although the loss of retinal ganglion cells (RGCs) is an established hallmark of glaucoma, reduction of intraocular pressure (IOP) is a...
Publikováno v:
International Journal of Medical and Health Sciences Research. 4:50-63
Background: Electronic Patient record (EPR) links consumers, payers and providers across the continuum of care and provides relevant information to them. It is essential that information can be accessed from anywhere in the healthcare delivery system
Autor:
Somaia Mohamed, Alexandra Mary Kelada, Amy M. Kilbourne, Sidney Zisook, Grant D. Huang, Gary R. Johnson, Kousick Biswas, Kimberly R. Weingart, Ilanit Young, Julia E. Vertrees, Martha Gerrity, David Lawrence, Theresa Gleason, Stephen R. Marder, Mary LeGwin, Katherine A. Kirkwood, Lori L. Davis, Peter D. Guarino, Paul B. Hicks, Peijun Chen, Jean Yoon
Publikováno v:
Psychiatry Research. 229:760-770
Because two-thirds of patients with Major Depressive Disorder do not achieve remission with their first antidepressant, we designed a trial of three "next-step" strategies: switching to another antidepressant (bupropion-SR) or augmenting the current